avenanthramide B : A monohydroxybenzoic acid resulting from the formal condensation of the carboxy group of ferulic acid with the amino group of 2-amino-5-hydroxybenzoic acid. It is an oat phytoalexin produced in response to pathogen attack and elicitation. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
| ID Source | ID |
|---|---|
| PubMed CID | 10087955 |
| CHEBI ID | 167489 |
| SCHEMBL ID | 4671925 |
| SCHEMBL ID | 6013366 |
| MeSH ID | M0542491 |
| Synonym |
|---|
| 5-hydroxy-2-{[(2e)-3-(4-hydroxy-3-methoxyphenyl)prop-2-enoyl]amino}benzoic acid |
| avenanthramide 1 |
| n-[4'-hydroxy-3'-methoxy-(e)-cinnamoyl]-5-hydroxyanthranilic acid |
| 108605-69-2 |
| avenanthramide 2f |
| avenanthramide b |
| avenanthramide bf |
| 5-hydroxy-2-{[(2e)-3-(4-hydroxy-3-methoxyphenyl)-1-oxo-2-propenyl]amino}benzoic acid |
| n-feruloyl-5-hydroxyanthranilic acid |
| CHEBI:167489 |
| benzoic acid, 5-hydroxy-2-[[(2e)-3-(4-hydroxy-3-methoxyphenyl)-1-oxo-2-propen-1-yl]amino]- |
| 5-hydroxy-2-(((2e)-3-(4-hydroxy-3-methoxyphenyl)-2-propenoyl)amino)benzoic acid |
| f8bq5730il , |
| benzoic acid, 5-hydroxy-2-(((2e)-3-(4-hydroxy-3-methoxyphenyl)-1-oxo-2-propen-1-yl)amino)- |
| unii-f8bq5730il |
| SCHEMBL4671925 |
| SCHEMBL6013366 |
| DTXSID50148603 |
| (z)-n-feruloyl-5-hydroxyanthranilic acid |
| 5-hydroxy-2-[(2e)-3-(4-hydroxy-3-methoxyphenyl)prop-2-enamido]benzoic acid |
| avenanthramide b, analytical standard |
| n-(4'-hydroxy-3'methoxy-(e)-cinnamoyl)-5-hydroxyanthranilic acid |
| 5-hydroxy-2-[[(e)-3-(4-hydroxy-3-methoxyphenyl)prop-2-enoyl]amino]benzoic acid |
| Q27277808 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " Although the bioavailability of AVAs has been investigated previously, little is known about their metabolism." | ( Oat avenanthramide-C (2c) is biotransformed by mice and the human microbiota into bioactive metabolites. Chen, H; Fu, J; McBride, J; Sang, S; Wang, P; Zhu, Y, 2015) | 0.42 |
| Role | Description |
|---|---|
| phytoalexin | A toxin made by a plant that acts against an organism attacking it. |
| antineoplastic agent | A substance that inhibits or prevents the proliferation of neoplasms. |
| apoptosis inducer | Any substance that induces the process of apoptosis (programmed cell death) in multi-celled organisms. |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Class | Description |
|---|---|
| monohydroxybenzoic acid | Any hydroxybenzoic acid having a single phenolic hydroxy substituent on the benzene ring. |
| cinnamamides | An enamide which is cinnamamide or a derivative of cinnamamide obtained by replacement of one or more of its hydrogens. |
| secondary carboxamide | A carboxamide resulting from the formal condensation of a carboxylic acid with a primary amine; formula RC(=O)NHR(1). |
| monomethoxybenzene | Compounds containing a benzene skeleton substituted with one methoxy group. |
| phenols | Organic aromatic compounds having one or more hydroxy groups attached to a benzene or other arene ring. |
| amidobenzoic acid | |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (13.07) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||